Literature DB >> 18842102

Ovarian cancer.

Kathleen R Cho1, Ie-Ming Shih.   

Abstract

Ovarian carcinomas are a heterogeneous group of neoplasms and are traditionally subclassified based on type and degree of differentiation. Although current clinical management of ovarian carcinoma largely fails to take this heterogeneity into account, it is becoming evident that each major histological type has characteristic genetic defects that deregulate specific signaling pathways in the tumor cells. Moreover, within the most common histological types, the molecular pathogenesis of low-grade versus high-grade tumors appears to be largely distinct. Mouse models of ovarian carcinoma have been developed that recapitulate many of the morphological features, biological behavior, and gene-expression patterns of selected subtypes of ovarian cancer. Such models will likely prove useful for studying ovarian cancer biology and for preclinical testing of molecularly targeted therapeutics, which may ultimately lead to better clinical outcomes for women with ovarian cancer.

Entities:  

Mesh:

Year:  2009        PMID: 18842102      PMCID: PMC2679364          DOI: 10.1146/annurev.pathol.4.110807.092246

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  142 in total

Review 1.  Prevalence of endometriosis in ovarian cancer.

Authors:  H Yoshikawa; H Jimbo; S Okada; K Matsumoto; T Onda; T Yasugi; Y Taketani
Journal:  Gynecol Obstet Invest       Date:  2000       Impact factor: 2.031

Review 2.  Molecular genetic defects in endometriosis.

Authors:  E J Thomas; I G Campbell
Journal:  Gynecol Obstet Invest       Date:  2000       Impact factor: 2.031

Review 3.  Precursor lesions of ovarian epithelial malignancy.

Authors:  K M Feeley; M Wells
Journal:  Histopathology       Date:  2001-02       Impact factor: 5.087

4.  beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.

Authors:  C Gamallo; J Palacios; G Moreno; J Calvo de Mora; A Suárez; A Armas
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

5.  HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.

Authors:  A M Afify; B A Werness; H F Mark
Journal:  Exp Mol Pathol       Date:  1999-06       Impact factor: 3.362

6.  A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary.

Authors:  K A Bell; R J Kurman
Journal:  Am J Surg Pathol       Date:  2000-11       Impact factor: 6.394

7.  beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours.

Authors:  K Wright; P Wilson; S Morland; I Campbell; M Walsh; T Hurst; B Ward; M Cummings; G Chenevix-Trench
Journal:  Int J Cancer       Date:  1999-08-27       Impact factor: 7.396

Review 8.  BRAF(E600) in benign and malignant human tumours.

Authors:  C Michaloglou; L C W Vredeveld; W J Mooi; D S Peeper
Journal:  Oncogene       Date:  2007-08-27       Impact factor: 9.867

Review 9.  Early events in the pathogenesis of epithelial ovarian cancer.

Authors:  Charles N Landen; Michael J Birrer; Anil K Sood
Journal:  J Clin Oncol       Date:  2008-01-14       Impact factor: 44.544

10.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.

Authors:  Joshua Z Press; Alessandro De Luca; Niki Boyd; Sean Young; Armelle Troussard; Yolanda Ridge; Pardeep Kaurah; Steve E Kalloger; Katherine A Blood; Margaret Smith; Paul T Spellman; Yuker Wang; Dianne M Miller; Doug Horsman; Malek Faham; C Blake Gilks; Joe Gray; David G Huntsman
Journal:  BMC Cancer       Date:  2008-01-22       Impact factor: 4.430

View more
  299 in total

1.  Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis.

Authors:  Elisabetta Kuhn; Alan Meeker; Tian-Li Wang; Ann Smith Sehdev; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

2.  Quantitative imaging reveals heterogeneous growth dynamics and treatment-dependent residual tumor distributions in a three-dimensional ovarian cancer model.

Authors:  Jonathan P Celli; Imran Rizvi; Conor L Evans; Adnan O Abu-Yousif; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2010 Sep-Oct       Impact factor: 3.170

3.  Targeting progesterone signaling prevents metastatic ovarian cancer.

Authors:  Olga Kim; Eun Young Park; Sun Young Kwon; Sojin Shin; Robert E Emerson; Yong-Hyun Shin; Francesco J DeMayo; John P Lydon; Donna M Coffey; Shannon M Hawkins; Lawrence A Quilliam; Dong-Joo Cheon; Facundo M Fernández; Kenneth P Nephew; Adam R Karpf; Martin Widschwendter; Anil K Sood; Robert C Bast; Andrew K Godwin; Kathy D Miller; Chi-Heum Cho; Jaeyeon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

4.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Authors:  Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

5.  The loss of Hoxa5 function causes estrous acyclicity and ovarian epithelial inclusion cysts.

Authors:  Gaëlle Gendronneau; Olivier Boucherat; Josée Aubin; Margot Lemieux; Lucie Jeannotte
Journal:  Endocrinology       Date:  2012-02-07       Impact factor: 4.736

Review 6.  Pathogenesis of ovarian cancer: clues from selected overexpressed genes.

Authors:  Ie-Ming Shih; Ben Davidson
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

7.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

8.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Authors:  Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2010-01-15

9.  Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies.

Authors:  Francesmary Modugno; Zhuxuan Fu; Susan J Jordan; Aocs Group; Jenny Chang-Claude; Renée T Fortner; Marc T Goodman; Kirsten B Moysich; Joellen M Schildkraut; Andrew Berchuck; Elisa V Bandera; Bo Qin; Rebecca Sutphen; John R McLaughlin; Usha Menon; Susan J Ramus; Simon A Gayther; Aleksandra Gentry-Maharaj; Chloe Karpinskyj; Celeste L Pearce; Anna H Wu; Harvey A Risch; Penelope M Webb
Journal:  Eur J Epidemiol       Date:  2020-09-21       Impact factor: 8.082

10.  Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.

Authors:  Etsuko Miyagi; Yasuyo Maruyama; Tae Mogami; Reiko Numazaki; Atsuko Ikeda; Hiroshi Yamamoto; Fumiki Hirahara
Journal:  Int J Clin Oncol       Date:  2016-09-13       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.